Ascendia

  MARKET NEWS

Alvotech & Teva Announce FDA Approval of  Biosimilar to Stelara
CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise
Atossa Therapeutics & Quantum Leap Healthcare Announce Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib in Women With ER+/HER2- Breast Cancer
SAB Biotherapeutics Provides SAB-142 Trial Update
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators With Issuance of Patent
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis

  FEATURED EDITORIAL

  COMPANY PROFILE

Mikron Automation is your worldwide partner for advanced assembly solutions. Our solutions are reliable and tailored to complex products. At Mikron we are committed to delivering the best assembly systems and services throughout the product’s entire life cycle. With our extensive engineering expertise, scalable platforms, and lifelong support, we ensure the success of our clients. With more than 4,000 assembly and test systems in use worldwide, our team has unique process expertise and the rigor for complex project management in a wide range of industries. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment

Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….

Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership

Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership

Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….

Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & 0-Million Private Placement

Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….

  WHITEPAPERS & WEBINARS

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s latest whitepaper outlines the key parameters that drug developers should considering while evaluating oral delivery …

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 1 – Nasal Drug Delivery
May 8 – Capsules